ADC Therapeutics SA (ADCT) vs Akebia Therapeutics (AKBA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
ADC Therapeutics SA (ADCT) has outperformed Akebia Therapeutics (AKBA) over the past year, losing 67.1% versus a loss of 70.4%. Over five years, AKBA leads with a -69.4% price change compared with -94.4% for ADCT. Akebia Therapeutics is the larger company by market cap ($242.0 million vs $181.3 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADCT | AKBA |
|---|---|---|
| Share price | $1.42 | $0.8734 |
| Market cap | $181.29M | $242.02M |
| 1-day change | +11.81% | -0.58% |
| YTD return | -59.77% | -45.75% |
| 1-year return | -67.05% | -70.39% |
| 5-year return | -94.42% | -69.35% |
| EPS (TTM) | $-0.60 | $-0.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.98 | $3.20 |
| 52-week low | $0.78 | $0.814 |
| Distance from 52-week high | -71.49% | -72.71% |
| Analyst consensus | none | none |
| Avg. price target upside | +134.51% | +348.82% |
| Average volume | 1.34M | 6.09M |
| Shares outstanding | 127.67M | 277.11M |
| Employees | 188 | 194 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About ADC Therapeutics SA
ADCT stock →ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.
Health Care · Biotechnology: Pharmaceutical Preparations · 188 employees
About Akebia Therapeutics
AKBA stock →Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
Health Care · Biotechnology: Pharmaceutical Preparations · 194 employees
ADCT vs AKBA FAQ
Which is bigger, ADC Therapeutics SA or Akebia Therapeutics?
Akebia Therapeutics (AKBA) is larger, with a market capitalization of $242.02M compared with $181.29M for ADC Therapeutics SA (ADCT).
Which stock has performed better over the past year, ADCT or AKBA?
ADCT returned -67.05% over the past 12 months, compared with -70.39% for AKBA (price return, excluding dividends). Past performance does not predict future results.
Are ADC Therapeutics SA and Akebia Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.